Wegovy injection
An injectable semaglutide medicine used for weight management.
Wegovy pill
A once-daily semaglutide pill used for weight management.
Ozempic
An injectable semaglutide medicine for type 2 diabetes.
Novo Nordisk makes medicines for diabetes and obesity, including Wegovy for weight management and Ozempic for type 2 diabetes. Its medicines reach patients through healthcare providers and pharmacies, with payment coming from insurers and public health programs or directly from patients. It also develops medicines for other conditions, including rare diseases.
Built from Novo Nordisk A/S’s own filings with the U.S. Securities and Exchange Commission (SEC). Figures are as reported, with per-share history restated onto today’s share basis. This company files in DKK. Figures are converted to US dollars at $1.00 = 6.7461 DKK, the current rate, applied to every period alike — so growth and margins are the company’s own and not the exchange rate’s. This describes a business — it is not investment advice and not a recommendation to buy or sell anything.
$41.10+1.0%Nov 11 close
Figures through September 30, 2026, from the 6-K filed November 4, 2026
Novo Nordisk sells prescription medicines for diabetes and obesity to patients and the health systems, insurers and pharmacies that pay for them.
The themes Novo Nordisk A/S is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Graded A or B and worth $2B or more: A first, then the largest.
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
Grade C+
The band under the price shows the grade on each date, built only from filings that were public by then.
Showing 2 of 16 quarters of Novo Nordisk A/S’s grade history. The other 14 go back to February 2018.
